Multiple immune parameters such as PD-1 expression in tumor infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMC) have been described in human and were proposed as predictive of anti-PD-1 clinical response (20–22). The gene discussed is PDCD1; the disease is neoplasm.